-
Something wrong with this record ?
Inhibition of human serine racemase, an emerging target for medicinal chemistry
J. Jirásková-Vaníčková, R. Ettrich, B. Vorlová, HE. Hoffman, M. Lepšík, P. Jansa, J. Konvalinka,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Adenosine Triphosphate metabolism MeSH
- Enzyme Inhibitors pharmacology MeSH
- Drug Delivery Systems MeSH
- Humans MeSH
- Nervous System Diseases drug therapy physiopathology MeSH
- Racemases and Epimerases antagonists & inhibitors metabolism MeSH
- Drug Design MeSH
- Receptors, N-Methyl-D-Aspartate drug effects metabolism MeSH
- Serine metabolism MeSH
- Binding Sites MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Proteins of glutamatergic NMDA receptor signaling pathways have been studied as targets for intervention in a variety of neuropathological conditions, including neurodegenerations, epilepsy, neuropathic pain, drug addiction, and schizophrenia. High activity NMDA-blocking agents have been designed to treat some of these disorders; however, their effect is often compromised by undesirable side effects. Therefore, alternative ways of modulating NMDA receptor function need to be sought after. The opening of the NMDA receptor ion channel requires occupation of two distinct binding sites, the glutamate site and the glycine site. It has been shown that D-serine, rather than glycine, can trigger the physiological NMDA receptor function. D-serine is a product of the activity of a specific enzyme, serine racemase (SR), which was identified a decade ago. SR has therefore emerged as a new potential target for the NMDA-receptor-based diseases. There is evidence linking increased levels of D-Ser to amyotrophic lateral sclerosis and Alzheimer's disease and decreased concentrations of D-serine to schizophrenia. SR is a pyridoxal-5'-phosphate dependent enzyme found in the cytosol of glial and neuronal cells. It is activated by ATP, divalent cations like Mg(2+) or Ca(2+), and reducing agents. This paper reviews the present literature on the activity and inhibition of mammalian SRs. It summarizes approaches that have been applied to design SR inhibitors and lists the known active compounds. Based on biochemical and docking analyses, i) we delineate for the first time the ATP binding site of human SR, and ii) we suggest possible mechanisms of action for the active compounds. In the end, we discuss the SR features that make the discovery of its inhibitors a challenging, yet very important, task of medicinal chemistry.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027841
- 003
- CZ-PrNML
- 005
- 20121207092935.0
- 007
- ta
- 008
- 120817s2011 ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.2174/138945011795677755 $2 doi
- 035 __
- $a (PubMed)21291385
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Jirásková, Jana $7 xx0102285 $u Gilead Sciences and IOCB Research Center Prague, Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 245 10
- $a Inhibition of human serine racemase, an emerging target for medicinal chemistry / $c J. Jirásková-Vaníčková, R. Ettrich, B. Vorlová, HE. Hoffman, M. Lepšík, P. Jansa, J. Konvalinka,
- 520 9_
- $a Proteins of glutamatergic NMDA receptor signaling pathways have been studied as targets for intervention in a variety of neuropathological conditions, including neurodegenerations, epilepsy, neuropathic pain, drug addiction, and schizophrenia. High activity NMDA-blocking agents have been designed to treat some of these disorders; however, their effect is often compromised by undesirable side effects. Therefore, alternative ways of modulating NMDA receptor function need to be sought after. The opening of the NMDA receptor ion channel requires occupation of two distinct binding sites, the glutamate site and the glycine site. It has been shown that D-serine, rather than glycine, can trigger the physiological NMDA receptor function. D-serine is a product of the activity of a specific enzyme, serine racemase (SR), which was identified a decade ago. SR has therefore emerged as a new potential target for the NMDA-receptor-based diseases. There is evidence linking increased levels of D-Ser to amyotrophic lateral sclerosis and Alzheimer's disease and decreased concentrations of D-serine to schizophrenia. SR is a pyridoxal-5'-phosphate dependent enzyme found in the cytosol of glial and neuronal cells. It is activated by ATP, divalent cations like Mg(2+) or Ca(2+), and reducing agents. This paper reviews the present literature on the activity and inhibition of mammalian SRs. It summarizes approaches that have been applied to design SR inhibitors and lists the known active compounds. Based on biochemical and docking analyses, i) we delineate for the first time the ATP binding site of human SR, and ii) we suggest possible mechanisms of action for the active compounds. In the end, we discuss the SR features that make the discovery of its inhibitors a challenging, yet very important, task of medicinal chemistry.
- 650 _2
- $a adenosintrifosfát $x metabolismus $7 D000255
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a vazebná místa $7 D001665
- 650 _2
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a inhibitory enzymů $x farmakologie $7 D004791
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nemoci nervového systému $x farmakoterapie $x patofyziologie $7 D009422
- 650 _2
- $a racemasy a epimerasy $x antagonisté a inhibitory $x metabolismus $7 D019998
- 650 _2
- $a receptory N-methyl-D-aspartátu $x účinky léků $x metabolismus $7 D016194
- 650 _2
- $a serin $x metabolismus $7 D012694
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Ettrich, Rudiger
- 700 1_
- $a Vorlová, Barbora
- 700 1_
- $a Hoffman, Hillary E
- 700 1_
- $a Lepšík, Martin
- 700 1_
- $a Jansa, Petr
- 700 1_
- $a Konvalinka, Jan
- 773 0_
- $w MED00007902 $t Current drug targets $x 1873-5592 $g Roč. 12, č. 7 (2011), s. 1037-55
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21291385 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121207093009 $b ABA008
- 999 __
- $a ok $b bmc $g 949883 $s 785187
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 12 $c 7 $d 1037-55 $i 1873-5592 $m Current drug targets $n Curr Drug Targets $x MED00007902
- LZP __
- $a Pubmed-20120817/11/03